European Heart Journal Advance Access published online on January 11, 2007
European Heart Journal, doi:10.1093/eurheartj/ehl449
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term clinical variation of NT-proBNP in stable chronic heart failure patients
1 Department of Cardiology and Endocrinology, Clinic E, Frederiksberg University Hospital, Ndr. Fasanvej 57–59, DK-2000 Frederiksberg, Denmark
2 Department of Cardiology, The Heart Centre, Rigshospitalet University Hospital, DK-2100 Copenhagen, Denmark
3 Department of Clinical Physiology and Nuclear Medicine and PET, Rigshospitalet University Hospital, DK-2100 Copenhagen, Denmark
4 Cluster for Molecular Imaging, Department of Medical Physiology, University of Copenhagen, DK-2200 Copenhagen, Denmark
Received 31 March 2006; revised 21 November 2006; accepted 30 November 2006.
* Corresponding author. Tel: +45 38 16 43 24; fax: +45 38 16 43 59. E-mail address: morten.schou{at}fh.hosp.dk
Aims Here, the aim is to assess long-term clinical variation (CV) of N-terminal pro-brain natriuretic peptide (NT-proBNP) in stable chronic heart failure (CHF) patients. The proposed use of NT-proBNP for monitoring of CHF patients will require accurate information about long-term CV of the peptide.
Methods and results Medication, biochemical variables, and NYHA class were recorded at 1-year and 2-year follow-up in patients treated in our heart failure clinic. Only patients without changes in medication and the NYHA class who were not hospitalized or died in the period from first follow-up to 12 months after the second follow-up were included. A total of 78 patients fulfilled the criteria, and year-to-year CV was calculated to 30% (median) (range: 0–111%) (% changes range: –87 to 397%). Log transformation of NT-proBNP (skewed to the right) reduced the year-to-year CV to 4.7% (range: 0–22%) (% changes range: –18 to 38%).
Conclusion Long-term CV of plasma concentrations of NT-proBNP in stable CHF patients is 30%, but the variation is substantial. Therefore, high long-term CV of NT-proBNP does not necessarily carry prognostic significance within the subsequent 12 months. Plasma concentrations of NT-proBNP followed a lognormal distribution, and the low CV of log(NT-proBNP) indicate that NT-proBNP levels are constant during stable conditions.
Key Words: Chronic heart failure • Natriuretic peptides • Long-term variation
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Frankenstein, A. Remppis, J. Frankenstein, G. Hess, D. Zdunek, K. Slottje, H. A. Katus, and C. Zugck Variability of N-Terminal Probrain Natriuretic Peptide in Stable Chronic Heart Failure and Its Relation to Changes in Clinical Variables Clin. Chem., May 1, 2009; 55(5): 923 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rosenberg, M. Schou, F. Gustafsson, J. Badskjaer, and P. Hildebrandt Prognostic threshold levels of NT-proBNP testing in primary care Eur. Heart J., January 1, 2009; 30(1): 66 - 73. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Vogelsang, R. J. Jensen, A. L. Monrad, K. Russ, U. H. Olesen, B. Hesse, and A. Kjaer Independent effects of both right and left ventricular function on plasma brain natriuretic peptide Eur J Heart Fail, September 1, 2007; 9(9): 892 - 896. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Luthje, D. Vollmann, T. Drescher, P. Schott, D. Zenker, G. Hasenfuss, and C. Unterberg Intrathoracic impedance monitoring to detect chronic heart failure deterioration: Relationship to changes in NT-proBNP Eur J Heart Fail, June 1, 2007; 9(6-7): 716 - 722. [Abstract] [Full Text] [PDF]
|
|